En el mundo empresarial actual, la gestión efectiva del talento es fundamental para el éxito y la competitividad de una organización. Afortunadamente, la tecnología ha evolucionado para brindar soluciones inteligentes que simplifican y mejoran este proceso. En este art&ia …
Beneficios del software de RRHH para mejorar la gestión de talento humano Read More »
New data from the HARMONIE Phase 3b clinical trial show an 83.21% reduction in hospitalizations due to RSV-related LRTD in infants under 12 months of age who received a single dose of nirsevimab, compared to infants who received no RSV intervention.1.
Willow Biosciences Inc. has released its financial and operating results for the three months ended March 31, 2023, reporting significant progress to its operational platform and strong liquidity.
Willow Biosciences Reports First Quarter 2023 Results Read More »
Cellectis published an article in Frontiers Bioenginnering, demonstrating the efficacy of its TALEN® engineered FAP UCART-cells in cancer-associated fibroblast depletion, reduction of desmoplasia and tumor infiltration.
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023.
An imported version of Nefecon delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the “Beijing Puhui Health Insurance Program.” Nefecon is a first-in-disease treatment for adults with primary immunoglobulin A nephropathy.
Mirion Technologies, Inc. announced the pricing of an underwritten public offering of 7,000,000 shares of Mirion’s Class A common stock by certain selling stockholders at a price to the public of $7.65 per share.
Mirion Technologies Announces Pricing of Public Offering by Selling Stockholders Read More »
IntraOp Medical Corporation announced the world’s first Phase II Electron FLASH Trial.
Walgreens Boots Alliance, Inc. announced that it has sold shares of AmerisourceBergen Corporation common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 of the Securities Act of 1933, as amended, for current proceeds of approximately $644 million.
